Orchestra BioMed Holdings, Inc. (ticker: OBIO) is an NASDAQ-listed surgical & medical instruments & apparatus company. DredgeCap's structured extraction of OBIO's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. OBIO reported $110K in revenue and -$20.69M for the period ending 2026-03-31, with operating cash flow of -$22.17M. Cash and equivalents stood at $28.37M (up 54.6% year-over-year). Total assets of $100.66M exceed total liabilities of $49.69M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
OBIO SEC Filings
Full cached SEC EDGAR filing history for OBIO, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.